MA31865B1 - Dérivés isoxazolo-pyridine - Google Patents
Dérivés isoxazolo-pyridineInfo
- Publication number
- MA31865B1 MA31865B1 MA32871A MA32871A MA31865B1 MA 31865 B1 MA31865 B1 MA 31865B1 MA 32871 A MA32871 A MA 32871A MA 32871 A MA32871 A MA 32871A MA 31865 B1 MA31865 B1 MA 31865B1
- Authority
- MA
- Morocco
- Prior art keywords
- optionally substituted
- 7alkyl
- isoxazolo
- halo
- pyridine
- Prior art date
Links
- NABZXASCLFSKLF-UHFFFAOYSA-N [1,2]oxazolo[4,3-b]pyridine Chemical class C1=CC=NC2=CON=C21 NABZXASCLFSKLF-UHFFFAOYSA-N 0.000 title abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Cette invention concerne des dérivés isoxazolo-pyridine représentés par la formule (i), dans laquelle x représente o ou nh; r1 représente phényle, pyridinyle, ou pyrimidinyle, chacun éventuellement substitué avec 1, 2 ou 3 halo, r2 représente h ou ch3 ou cf3; r3, r4, r5, et r6 représentent indépendamment les uns des autres h, c1-7alkyle éventuellement substitué, c1-7alkoxy éventuellement substitué, cn, halo, no2, s-c1-7alkyle, s(o)-c1-7alkyle, benzyloxy éventuellement substitué, -c(o)-ra, -c(o)-nrb rc, ou un sel pharmaceutiquement acceptable de ceux-ci. Les composés sont actifs sur le site de liaison aux récepteurs gaba a ?5 et ils sont utilisés pour le traitement de troubles cognitifs, tels que la maladie d'alzheimer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07122240 | 2007-12-04 | ||
| PCT/EP2008/066225 WO2009071476A1 (fr) | 2007-12-04 | 2008-11-26 | Dérivés isoxazolo-pyridine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31865B1 true MA31865B1 (fr) | 2010-11-01 |
Family
ID=40329314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32871A MA31865B1 (fr) | 2007-12-04 | 2010-05-27 | Dérivés isoxazolo-pyridine |
Country Status (33)
| Country | Link |
|---|---|
| US (6) | US20090143371A1 (fr) |
| EP (2) | EP2227467B1 (fr) |
| JP (1) | JP5301557B2 (fr) |
| KR (2) | KR20120102117A (fr) |
| CN (1) | CN101889010B (fr) |
| AR (1) | AR069523A1 (fr) |
| AU (1) | AU2008333326B2 (fr) |
| BR (1) | BRPI0820112B8 (fr) |
| CA (1) | CA2707648C (fr) |
| CL (1) | CL2008003591A1 (fr) |
| CO (1) | CO6351788A2 (fr) |
| CR (1) | CR11454A (fr) |
| CY (2) | CY1116119T1 (fr) |
| DK (2) | DK2227467T3 (fr) |
| EC (1) | ECSP10010230A (fr) |
| ES (2) | ES2550994T3 (fr) |
| HR (2) | HRP20150348T1 (fr) |
| HU (1) | HUE025545T2 (fr) |
| IL (1) | IL205759A (fr) |
| MA (1) | MA31865B1 (fr) |
| MX (1) | MX2010005717A (fr) |
| MY (1) | MY156747A (fr) |
| NZ (1) | NZ585308A (fr) |
| PE (2) | PE20130242A1 (fr) |
| PL (2) | PL2227467T3 (fr) |
| PT (2) | PT2767536E (fr) |
| RS (2) | RS53877B1 (fr) |
| RU (1) | RU2484091C2 (fr) |
| SI (2) | SI2227467T1 (fr) |
| TW (1) | TWI363624B (fr) |
| UA (1) | UA100132C2 (fr) |
| WO (1) | WO2009071476A1 (fr) |
| ZA (1) | ZA201003631B (fr) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2227467B1 (fr) | 2007-12-04 | 2014-12-31 | F. Hoffmann-La Roche AG | Dérivés isoxazolo-pyridine |
| JP2012506386A (ja) * | 2008-10-21 | 2012-03-15 | メタボレックス， インコーポレイテッド | アリールｇｐｒ１２０受容体アゴニストおよびその使用 |
| EP3725775A1 (fr) | 2009-02-17 | 2020-10-21 | Syntrix Biosystems, Inc. | Pyridine- et pyrimidinecarboxamides comme modulateurs du cxcr2 |
| US8389550B2 (en) * | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
| US8222246B2 (en) * | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
| US20100280019A1 (en) | 2009-04-30 | 2010-11-04 | Roland Jakob-Roetne | Isoxazoles |
| WO2010127976A1 (fr) * | 2009-05-05 | 2010-11-11 | F. Hoffmann-La Roche Ag | Dérivés d'isoxazole-pyridine |
| AU2010244552A1 (en) * | 2009-05-05 | 2011-09-29 | F. Hoffmann-La Roche Ag | Isoxazole-pyrazole derivatives |
| SG175869A1 (en) * | 2009-05-05 | 2011-12-29 | Hoffmann La Roche | Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders |
| AU2010244555A1 (en) * | 2009-05-07 | 2011-11-03 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives as GABA modulators |
| MX2012003394A (es) * | 2009-09-21 | 2012-08-15 | Univ Vanderbilt | Analogos de la nicotinamida de o-bencilo como moduladores alostéricos positivos del mglur5. |
| MX336731B (es) | 2010-01-28 | 2016-01-28 | Harvard College | Composiciones y metodos para potenciar la actividad de proteasoma. |
| EP2595985A1 (fr) | 2010-07-19 | 2013-05-29 | Syngenta Participations AG | Composés d'isoxazole, d'isothiazole, de furane et de thiophène utilisables en tant que microbicides |
| EP2595984A1 (fr) | 2010-07-19 | 2013-05-29 | Syngenta Participations AG | Microbicides |
| AU2011293612B2 (en) * | 2010-08-23 | 2015-11-26 | Syntrix Biosystems Inc. | Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators |
| EP2457569A1 (fr) | 2010-11-05 | 2012-05-30 | F. Hoffmann-La Roche AG | Utilisation de composés pharmaceutiques actifs pour le traitement de conditions du système nerveux central |
| NZ608592A (en) * | 2010-11-05 | 2015-08-28 | Hoffmann La Roche | Use of active pharmaceutical compounds for the treatment of central nervous system conditions |
| RS58718B1 (sr) | 2011-05-12 | 2019-06-28 | Proteostasis Therapeutics Inc | Regulatori proteostaze |
| US8785435B2 (en) * | 2011-10-20 | 2014-07-22 | Hoffmann-La Roche Inc. | Solid forms |
| US8604062B2 (en) * | 2011-10-20 | 2013-12-10 | Hoffman-La Roche Inc. | Process for the preparation of isoxazolyl-methoxy nicotinic acids |
| DK3738434T3 (da) | 2011-12-28 | 2023-12-04 | Global Blood Therapeutics Inc | Mellemprodukter til opnåelse af substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsoxygenering |
| WO2013102145A1 (fr) * | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Composés d'aldéhydes hétéroaryles substitués et leurs procédés d'utilisation dans l'accroissement de l'oxygénation tissulaire |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| CA2876778A1 (fr) | 2012-06-26 | 2014-01-03 | Saniona Aps | Derive de phenyle triazole et son utilisation pour moduler le complexe du recepteur gabaa |
| WO2014001280A1 (fr) | 2012-06-26 | 2014-01-03 | Aniona Aps | Dérivé de phényle triazole et son utilisation pour moduler le complexe du récepteur gabaa |
| WO2014001278A1 (fr) | 2012-06-26 | 2014-01-03 | Aniona Aps | Dérivé de phényle triazole et son utilisation pour moduler le complexe du récepteur gabaa |
| WO2014001279A1 (fr) | 2012-06-26 | 2014-01-03 | Aniona Aps | Dérivé de phényle triazole et son utilisation pour moduler le complexe du récepteur gabaa |
| KR20150033679A (ko) | 2012-06-26 | 2015-04-01 | 사니오나 에이피에스 | 페닐 트리아졸 유도체 및 이의 gabaa 수용체 복합체 조절용 용도 |
| US9849135B2 (en) | 2013-01-25 | 2017-12-26 | President And Fellows Of Harvard College | USP14 inhibitors for treating or preventing viral infections |
| BR112015021982B1 (pt) * | 2013-03-15 | 2022-12-13 | Global Blood Therapeutics, Inc | Compostos e seus usos para a modulação de hemoglobina |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| AU2014237330A1 (en) | 2013-03-15 | 2015-09-17 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| KR102280614B1 (ko) | 2013-03-15 | 2021-07-21 | 글로벌 블러드 테라퓨틱스, 인크. | 헤모글로빈 조정을 위한 화합물 및 이의 용도 |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EP2792360A1 (fr) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide pour utilisation dans le traitement de HCV |
| US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
| WO2015073528A1 (fr) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Composés renforçant l'activité des protéasomes |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| SI3102208T2 (sl) | 2014-02-07 | 2024-10-30 | Global Blood Therapeutics, Inc. | Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida |
| JP2017071553A (ja) * | 2014-02-25 | 2017-04-13 | 味の素株式会社 | ヘテロ原子−メチレン−ヘテロ環構造を有する新規化合物 |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| CN106810542B (zh) * | 2015-11-30 | 2021-03-09 | 苏州开拓药业股份有限公司 | 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法 |
| US11020382B2 (en) | 2015-12-04 | 2021-06-01 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| AR108435A1 (es) | 2016-05-12 | 2018-08-22 | Global Blood Therapeutics Inc | Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído |
| TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| UA125524C2 (uk) * | 2016-12-08 | 2022-04-13 | Ф. Хоффманн-Ля Рош Аг | Ефірні похідні ізоксазолу як позитивні алостеричні модулятори рецептора гамк а альфа-5 |
| ES2987108T3 (es) | 2017-08-28 | 2024-11-13 | Univ Maryland | Nuevos moduladores del receptor de tipo A de ácido gamma aminobutírico para los trastornos del estado de ánimo |
| UY38031A (es) * | 2017-12-22 | 2019-07-31 | Bayer Ag | Hidroxiisoxazolinas y derivados de estos |
| AU2019286312B2 (en) * | 2018-06-13 | 2023-08-17 | F. Hoffmann-La Roche Ag | New isoxazolyl ether derivatives as GABA A alpha5 PAM |
| BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| HU231223B1 (hu) | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
| EP3860975B1 (fr) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulateurs de l'hémoglobine pour le traitement de la drépanocytose |
| WO2020163689A1 (fr) | 2019-02-08 | 2020-08-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Inhibiteurs de formation de 20-hete |
| EP4126858B1 (fr) | 2020-03-26 | 2026-03-18 | Richter Gedeon Nyrt. | Dérivés de 1,3-dihydro-2-pyrrolo[3,4-c]pyridine utilisés en tant que modulateurs du récepteur gabaa a5 |
| WO2022234271A1 (fr) | 2021-05-05 | 2022-11-10 | University College Cardiff Consultants Limited | Composés hétéroaryle pouvant être utilisés dans le traitement de troubles cognitifs |
| CN116854680A (zh) * | 2022-03-28 | 2023-10-10 | 上海赛默罗生物科技有限公司 | 异噁唑-杂环类衍生物、药物组合物和用途 |
| WO2024042043A1 (fr) * | 2022-08-24 | 2024-02-29 | Boehringer Ingelheim International Gmbh | Procédé évolutif pour la préparation d'un inhibiteur de glyt-1 |
| CN115286636A (zh) * | 2022-10-08 | 2022-11-04 | 上海赛默罗生物科技有限公司 | 烟酰胺晶型及其制备方法和用途 |
| WO2024251133A1 (fr) * | 2023-06-05 | 2024-12-12 | 武汉人福创新药物研发中心有限公司 | COMPOSÉ HÉTÉROCYCLIQUE EN TANT QUE MODULATEUR DU RÉCEPTEUR α5-GABAA ET SON UTILISATION |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3812225A1 (de) * | 1988-04-13 | 1989-10-26 | Basf Ag | Isoxazol(isothiazol)-5-carbonsaeureamide |
| WO2000008001A1 (fr) | 1998-08-07 | 2000-02-17 | Chiron Corporation | Isoxazoles substitues comme modulateurs de recepteur d'oestrogenes |
| DE19920791A1 (de) * | 1999-05-06 | 2000-11-09 | Bayer Ag | Substituierte Benzoylisoxazole |
| GB0125086D0 (en) | 2001-10-18 | 2001-12-12 | Merck Sharp & Dohme | Novel compounds |
| US20060148858A1 (en) | 2002-05-24 | 2006-07-06 | Tsuyoshi Maekawa | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity |
| GB0221443D0 (en) * | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
| AU2005245411B2 (en) * | 2004-05-14 | 2009-04-23 | Irm Llc | Compounds and compositions as PPAR modulators |
| ES2315912T3 (es) * | 2004-10-01 | 2009-04-01 | F. Hoffmann-La Roche Ag | Derivados de eter sustituido por hexafluorisopropanol. |
| WO2007002635A2 (fr) * | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Antagonistes cycliques a liaison c du recepteur p2y1, utiles pour traiter des etats pathologiques thrombotiques |
| CA2623043A1 (fr) * | 2005-09-19 | 2007-04-12 | F. Hoffman-La Roche Ag | Derives d'isoxazolo utilises en tant qu'agonistes inverses de gaba alpha5 |
| BRPI0617306A2 (pt) * | 2005-10-11 | 2011-07-19 | Hoffmann La Roche | derivados de isoxazol |
| BRPI0620146A2 (pt) * | 2005-12-23 | 2011-11-01 | Hoffmann La Roche | derivados de aril-isoxazolo-4-il-oxadiazol, processo para a preparação dos referidos derivados, medicamento que os contém e usos de um desses derivados |
| KR101121372B1 (ko) | 2005-12-27 | 2012-04-12 | 에프. 호프만-라 로슈 아게 | 아릴-이속사졸-4-일-이미다졸 유도체 |
| JP4864982B2 (ja) | 2005-12-27 | 2012-02-01 | エフ．ホフマン−ラ ロシュ アーゲー | アリール−イソオキサゾール−４−イル−イミダゾ［１，５−ａ］ピリジン誘導体 |
| AU2007207053B2 (en) | 2006-01-17 | 2012-05-24 | F. Hoffmann-La Roche Ag | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of Alzheimer's disease via GABA receptors |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| EP2227467B1 (fr) | 2007-12-04 | 2014-12-31 | F. Hoffmann-La Roche AG | Dérivés isoxazolo-pyridine |
| CA2706990C (fr) | 2007-12-04 | 2016-05-10 | F. Hoffmann-La Roche Ag | Derives d'isoxazolo-pyrazine |
| US20100280019A1 (en) * | 2009-04-30 | 2010-11-04 | Roland Jakob-Roetne | Isoxazoles |
-
2008
- 2008-11-26 EP EP08857137.7A patent/EP2227467B1/fr active Active
- 2008-11-26 UA UAA201008007A patent/UA100132C2/ru unknown
- 2008-11-26 EP EP14168581.8A patent/EP2767536B1/fr active Active
- 2008-11-26 HU HUE14168581A patent/HUE025545T2/en unknown
- 2008-11-26 KR KR1020127018310A patent/KR20120102117A/ko not_active Withdrawn
- 2008-11-26 WO PCT/EP2008/066225 patent/WO2009071476A1/fr not_active Ceased
- 2008-11-26 HR HRP20150348TT patent/HRP20150348T1/hr unknown
- 2008-11-26 SI SI200831370T patent/SI2227467T1/sl unknown
- 2008-11-26 CN CN2008801193998A patent/CN101889010B/zh active Active
- 2008-11-26 RS RS20150176A patent/RS53877B1/sr unknown
- 2008-11-26 JP JP2010536409A patent/JP5301557B2/ja active Active
- 2008-11-26 DK DK08857137.7T patent/DK2227467T3/en active
- 2008-11-26 BR BRPI0820112A patent/BRPI0820112B8/pt active IP Right Grant
- 2008-11-26 RS RS20150703A patent/RS54355B1/sr unknown
- 2008-11-26 PL PL08857137T patent/PL2227467T3/pl unknown
- 2008-11-26 SI SI200831532T patent/SI2767536T1/sl unknown
- 2008-11-26 NZ NZ585308A patent/NZ585308A/en unknown
- 2008-11-26 KR KR1020107012058A patent/KR101237576B1/ko active Active
- 2008-11-26 PT PT141685818T patent/PT2767536E/pt unknown
- 2008-11-26 MY MYPI2010002566A patent/MY156747A/en unknown
- 2008-11-26 CA CA2707648A patent/CA2707648C/fr active Active
- 2008-11-26 ES ES14168581.8T patent/ES2550994T3/es active Active
- 2008-11-26 ES ES08857137T patent/ES2531023T3/es active Active
- 2008-11-26 PT PT08857137T patent/PT2227467E/pt unknown
- 2008-11-26 MX MX2010005717A patent/MX2010005717A/es active IP Right Grant
- 2008-11-26 RU RU2010123923/04A patent/RU2484091C2/ru active
- 2008-11-26 DK DK14168581.8T patent/DK2767536T3/en active
- 2008-11-26 AU AU2008333326A patent/AU2008333326B2/en active Active
- 2008-11-26 PL PL14168581T patent/PL2767536T3/pl unknown
- 2008-12-01 PE PE2012002214A patent/PE20130242A1/es not_active Application Discontinuation
- 2008-12-01 PE PE2008002002A patent/PE20091073A1/es active IP Right Grant
- 2008-12-01 US US12/325,293 patent/US20090143371A1/en not_active Abandoned
- 2008-12-01 TW TW097146632A patent/TWI363624B/zh active
- 2008-12-02 CL CL2008003591A patent/CL2008003591A1/es unknown
- 2008-12-02 AR ARP080105242A patent/AR069523A1/es active IP Right Grant
-
2010
- 2010-05-13 IL IL205759A patent/IL205759A/en active IP Right Grant
- 2010-05-14 CO CO10058230A patent/CO6351788A2/es active IP Right Grant
- 2010-05-21 ZA ZA2010/03631A patent/ZA201003631B/en unknown
- 2010-05-21 CR CR11454A patent/CR11454A/es unknown
- 2010-05-27 MA MA32871A patent/MA31865B1/fr unknown
- 2010-06-03 EC EC2010010230A patent/ECSP10010230A/es unknown
-
2012
- 2012-02-10 US US13/370,444 patent/US8518974B2/en active Active
-
2013
- 2013-06-12 US US13/916,264 patent/US8877783B2/en active Active
- 2013-06-12 US US13/916,191 patent/US8877782B2/en active Active
- 2013-06-12 US US13/916,068 patent/US8846719B2/en active Active
- 2013-06-12 US US13/916,317 patent/US9073908B2/en active Active
-
2015
- 2015-03-16 CY CY20151100262T patent/CY1116119T1/el unknown
- 2015-11-09 CY CY20151100999T patent/CY1116902T1/el unknown
- 2015-11-20 HR HRP20151250TT patent/HRP20151250T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY156747A (en) | Isoxazolo-pyridine derivatives | |
| MA29807B1 (fr) | Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques. | |
| MA29335B1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
| MA27575A1 (fr) | Derives de 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazine-2-yl)-benzamide servant d'inhibiteurs de p2x7 pour le traitement de maladies inflammatoires | |
| MA32705B1 (fr) | Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation | |
| MA29805B1 (fr) | Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques | |
| MA42442B1 (fr) | Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate | |
| MA34450B1 (fr) | Dérivés de l'imidazopyridine, procédé pour leur préparation, et leur utilisation thérapeutique | |
| EA202090987A8 (ru) | Новые пролекарства на основе катехоламина для применения в лечении болезни паркинсона | |
| MA27754A1 (fr) | Pyrimidinones substituees | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| TNSN05104A1 (fr) | Derives de thiazole pour le traitement de troubles neurodegeneratifs | |
| NO20064726L (no) | Imidazolforbindelser for behandling av neurodegenerative forstyrrelser | |
| MA27569A1 (fr) | Derives de pyrrolo-pyrazole substitues servant d'inhibiteurs de kinases | |
| MA34451B1 (fr) | Dérivés de l'indolizine, procédé pour leur préparation, et leur utilisation thérapeutique | |
| MA31373B1 (fr) | Composes amino-heterocycliques | |
| MA29379B1 (fr) | Derives de pyrrolidine 3,4-substitues pour le traitement de l'hypertension | |
| MA35133B1 (fr) | Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5 | |
| MA38079A1 (fr) | Composés de 2-phényl-5-hétérocyclyl-tétrahydro-2h-pyran-3-amine destinés à être utilisés dans le traitement du diabète et de ses troubles associés | |
| MA29809B1 (fr) | N-[1,3,4]-thiadiazol-2-yl-benzenesulfonamides,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques | |
| TW200626573A (en) | Pyrimidone compound | |
| MA31742B1 (fr) | Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique | |
| TNSN04234A1 (fr) | Derives de n-acylaminobenzene comme inhibiteurs selectifs de la monoamine oxydase b | |
| TNSN05309A1 (fr) | Derives d'imidazole utilises comme antagonistes du recepteur du glutamate | |
| WO2007054444A3 (fr) | Derives du 3-aryl-isoxazole-4-carbonyl-benzofurane |